Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
RESEARCH TOOLSreports
Kiniksa Pharmaceuticals (KNSA) Stock Price & Analysis
360 Followers
KNSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.29 - $20.65
Previous Close$17.54
Volume207.04K
Average Volume (3M)499.78K
Market Cap
$611.03M
Enterprise ValueN/A
Total Cash (Recent Filing)$184.99M
Total Debt (Recent Filing)$13.52M
Price to Earnings (P/E)5.4
Beta0.19
Next Earnings
Oct 30, 2023EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.27
Shares Outstanding70,166,898
10 Day Avg. Volume275,018
30 Day Avg. Volume499,778
Standard Deviation0.19
R-Squared0.00076
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.09
Price to Sales (P/S)16.84
Price to Cash Flow (P/CF)-81.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$26.75Price Target Upside58.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Kiniksa Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $10.29 and its highest was $20.65 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Currently, no data Available
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Oct 30, 2023 which is in 40 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Jul 25, 2023. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of -$0.142 by $0.352.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is -$0.17.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 35,238,255 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.21 in its last earnings report, beating expectations of -$0.142. Following the earnings report the stock price went up 30.388%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Among the largest hedge funds holding Kiniksa Pharmaceuticals’s share is Baker Bros Advisors LP. It holds Kiniksa Pharmaceuticals’s shares valued at 40M.
---
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.75 (58.00% Upside)
$26.75 (58.00% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.62%
12-Months-Change
Fundamentals
Return on Equity
81.84%
Trailing 12-Months
Asset Growth
130.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
---
Top 5 ETFs holding KNSA
Vanguard Total Stock Market ETF
$15.40M
Vanguard Health Care ETF
$1.66M
iShares Russell 3000 ETF
$200.78K
Vanguard U.S. Momentum Factor ETF
$199.41K
Vanguard Russell 3000 ETF
$30.58K
Up to five ETFs with an Outperform Smart Score that hold KNSA. The ETFs are listed according to market value of KNSA within the ETF
---